What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?
How are you using telemedicine or other strategies to manage your patients with CLL during the COVID-19 pandemic?
How are you managing your patients with CLL during the COVID-19 pandemic? Here, I share my experiences during the height of the pandemic in New York City and offer recommendations to minimize the risk to your patients.
As a physician and CLL survivor, I share insights on the patient’s experience in the ongoing COVID-19 pandemic plus recommendations for counseling patients with CLL on how best to protect their physical and mental health.
Our understanding of how COVID-19 affects our patients with CLL continues to evolve. Here, I share my perspective on treatment modifications during the pandemic, using IVIg as COVID-19 prophylaxis, the role of BTK inhibition, and counseling patients on COVID-19 risk.
With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.
Here I discuss 2 interesting cases from my practice: an older patient who needed to initiate therapy but was afraid to come to the clinic and a patient who developed COVID-19 while receiving venetoclax.
What are the latest data on BTK inhibitors to treat COVID-19? How are you managing your patients with CLL going forward? Here, I share my experiences and thoughts on the implications of the latest data and emerging vaccine approvals for patients with CLL.
Download this living slideset from the live Webinar on the management of patients with CLL during the COVID-19 pandemic and check back often for updates as the situation evolves and more data are available.
Read expert answers to key questions asked by clinicians during a series of live Webinars focused on the interface of CLL and the COVID-19 pandemic, including COVID-19 outcomes in patients with CLL, minimizing COVID-19 risk, selecting CLL treatments during the pandemic, BTK and PI3K inhibition in patients with COVID-19, and considerations for when a COVID-19 vaccine is available.